Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Vomiting 2Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Triple Negative Breast Neoplasms 1Postoperative Nausea and Vomiting 1Papillomavirus Infections 1Ovarian Neoplasms 1Neoplasm Metastasis 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Gynecologic Cancer 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Carcinoma, Hepatocellular 1Carcinoma in Situ 1Carcinoma 1Burkitt Lymphoma 1Breast Neoplasms 1

Interventions

Rituximab 85Cyclophosphamide 80Prednisone 47Doxorubicin 43Lenalidomide 36Vincristine 34Magnetic Resonance Spectroscopy 29polatuzumab vedotin 28Gemcitabine 26Etoposide 26Specimen Handling 25fludarabine 23Biopsy 21Oxaliplatin 20CT-P10 20glofitamab 16tafasitamab 15obinutuzumab 15ibrutinib 13fludarabine phosphate 13zanubrutinib 12axicabtagene ciloleucel 12Immunotherapy, Adoptive 12Ifosfamide 12venetoclax 11pembrolizumab 11deltacortene 11prednylidene 10Prednisolone 10Leukapheresis 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Large B-Cell, Diffuse × Ondansetron × 1 year × Clear all
NCT00001337 2025-06-22

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
348 enrolled 15 charts
Lymphoid

Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡